Related Experiment Videos
Systemic therapy for advanced pancreatic cancer
Basil F El-Rayes1, Philip A Philip
1Division of Haematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Expert Review of Anticancer Therapy
|March 22, 2003
Summary
Pancreatic cancer survival remains poor, with limited success from 5-fluorouracil chemotherapy. New combination therapies show promise, but require further randomized trials for confirmation.
Area of Science:
- Oncology
- Medical Research
Background:
- Pancreatic cancer has a high mortality rate with limited long-term survival.
- Traditional 5-fluorouracil chemotherapy has shown minimal impact on patient outcomes.
Purpose of the Study:
- To review the efficacy of novel chemotherapeutic agents and combination therapies for pancreatic cancer.
- To highlight advancements in understanding pancreatic cancer biology for targeted therapy development.
Main Methods:
- Review of recent studies on pancreatic cancer treatment.
- Analysis of combination chemotherapy trials involving gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, docetaxel, and irinotecan.
Main Results:
- Gemcitabine demonstrates modest activity in pancreatic cancer.
- Combination chemotherapy regimens show improved objective response rates and survival, warranting further investigation.
- Advances in molecular biology have identified new therapeutic targets.
Conclusions:
- Current and future pancreatic cancer treatment strategies will integrate conventional cytotoxic agents with novel targeted therapies.
- Further randomized studies are essential to validate the benefits of new combination regimens.